|Bid||729.73 x 800|
|Ask||743.00 x 1000|
|Day's range||724.12 - 740.16|
|52-week range||538.01 - 837.55|
|Beta (5Y monthly)||0.22|
|PE ratio (TTM)||20.00|
|Earnings date||01 Aug 2023 - 07 Aug 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||889.32|
A mid-stage study data shows that treatment with Regeneron's (REGN) experimental antibody achieved a 71% objective response rate in heavily pre-treated multiple myeloma patients.
71% objective response rate, with 59% of patients achieving a very good partial response or better at the recommended 200 mg dose, per new data to be shared in an oral session at ASCO Benefit also observed across prespecified subgroups, including patients with high disease burden and aggressive disease Data from this trial to form the basis of planned regulatory submissions, starting with the FDA in 2023 TARRYTOWN, N.Y., May 25, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: R
Data demonstrate objective response rates from 56% to 63% across three independent cohorts of advanced melanoma patients – about double the rate historically seen with anti-PD-1 alone in similar settings – per trial results to be presented in an oral session at ASCO Clinically meaningful responses observed in post hoc analyses of populations of interest, including patients with poor prognosis factors, prior anti-PD-1 therapy in the adjuvant setting and varying tumor PD-L1 expression levels Pivot
Dupixent is the first and only investigational biologic for COPD that has demonstrated a significant reduction in moderate or severe acute exacerbations by 30% compared to placebo Dupixent is the first and only investigational biologic for COPD that has significantly improved lung function at 12 and 52 weeks, with numerical improvements seen as early as 2 weeks Dupixent significantly improved quality of life, with numerical improvements as early as 4 weeks after initiating treatment, and respira
When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, if you buy shares...
Regeneron (REGN) loses some of its gains as sales of its lead drug, Eylea, decline. Nevertheless, Dupixent sales boost the top line.
$75,000 Top Award Goes to 17-year-old Kaitlyn Wang for breakthrough innovation to accelerate exoplanet discovery in the largest international STEM competition for teensTARRYTOWN, N.Y. and WASHINGTON, D.C., May 19, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) announced that Kaitlyn Wang, 17, of San José, CA, won the $75,000 top award in the 2023 Regeneron International Science and Engineering Fair (Regeneron ISEF), the world’s large
TARRYTOWN, N.Y., May 18, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: TD Cowen 4th Annual Oncology Innovation Summit at 12:30 p.m. ET on Tuesday, May 30, 2023Jefferies Healthcare Conference at 8:30 a.m. ET on Wednesday, June 7, 2023 Goldman Sachs 44th Annual Global Healthcare Conference at 8:40 a.m. PT (11:40 a.m. ET) on Wednesday, June 14, 2023 The sessions may be accessed from the "Investors & Media" page of Regeneron
Decision ends nearly decade-long patent dispute related to Regeneron-invented Praluent® (alirocumab) TARRYTOWN, N.Y., May 18, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) applauds the United States Supreme Court’s unanimous opinion1 ending a nearly decade-long patent dispute related to the Regeneron-invented PCSK9 inhibitor, Praluent® (alirocumab). The decision affirms the United States Court of Appeals for the Federal Circuit’s opinion, which held that Amgen’s asserte
Regeneron Pharmaceuticals (NASDAQ:REGN) has had a rough month with its share price down 9.4%. However, stock prices are...
Economists at the U.S. Federal Reserve recently uttered the dreaded "R" word. They are now predicting a recession will come later this year. Investors have been bracing for this possibility for a while now, so it shouldn't come as too much of a surprise.
Key Insights The projected fair value for Regeneron Pharmaceuticals is US$1,053 based on 2 Stage Free Cash Flow to...
From what we can see, insiders were net sellers in Regeneron Pharmaceuticals, Inc.'s ( NASDAQ:REGN ) during the past 12...
Regeneron Pharmaceuticals (NASDAQ: REGN), a large-cap biotechnology company, is under heavy pressure today. Specifically, the biotech's stock was down by an unsightly 6.5% on heavy volume as of 12:19 p.m. ET Thursday afternoon. Regeneron's shares are moving southward in response to lower-than-expected sales of its flagship eye-care treatment, Eylea, during the first quarter of 2023.
Regeneron (REGN) beats earnings and sales estimates in first-quarter 2023 fueled by Dupixent. However, sales of the lead drug Eylea declined yet again.
While the top- and bottom-line numbers for Regeneron (REGN) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Regeneron (REGN) delivered earnings and revenue surprises of 9.08% and 8.12%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
First quarter 2023 revenues increased 7% to $3.16 billion versus first quarter 2022First quarter 2023 Dupixent® global net sales (recorded by Sanofi) increased 37% to $2.49 billion versus first quarter 2022First quarter 2023 EYLEA® U.S. net sales were $1.43 billionFirst quarter 2023 GAAP diluted EPS of $7.17 and non-GAAP diluted EPS(a) of $10.09; includes unfavorable $0.42 impact from acquired IPR&D chargeEuropean Commission approved Dupixent for atopic dermatitis in children aged 6 months to 5
Let us look at four big drug and biotech companies, REGN, ZTS, MRNA and NVO, which are gearing up for their earnings release.
Regeneron (REGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
LGND vs. REGN: Which Stock Is the Better Value Option?
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Oral presentations include interim results from pivotal trial of linvoseltamab (BCMAxCD3) in relapsed/refractory multiple myeloma and three cohorts of fianlimab (LAG-3 inhibitor) combined with Libtayo® (cemiplimab-rwlc) in advanced melanoma Ten total presentations to cover clinical research across six solid tumors and blood cancers TARRYTOWN, N.Y., May 02, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the presentation of new and updated data from its div
Regeneron's (REGN) first-quarter earnings are likely to have gotten a boost from the solid performance of Dupixent.
In the latest trading session, Regeneron (REGN) closed at $792.29, marking a +1.84% move from the previous day.